• Gore Range Capital

LEO Pharma Joins Gore Range Capital as Strategic Investor

Partnership melds firms' commitment to innovation in dermatology and patient-centric approach

NEW YORK--(BUSINESS WIRE)--Gore Range Capital (“Gore Range”), a venture capital firm focused on healthcare, announced today that LEO Pharma A/S, a global leader in medical dermatology, has made an investment through Gore Range’s Strategic Investment Program to expand LEO Pharma’s access to early and growth-stage dermatology related businesses.

Gore Range and LEO Pharma are an ideal strategic partnership as both firms share a mission to develop life-changing medical solutions through a patient-centric approach. Gore Range will partner with LEO Pharma's senior management to invest in companies and projects of mutual interest. Beyond capital, portfolio companies will benefit from LEO Pharma’s industry expertise and strong R&D capabilities and Gore Range’s experience in nurturing new enterprises.

“We are thrilled to partner with LEO Pharma, coupling our team’s expertise in dermatology with their global footprint, legacy, and commitment to improving patients’ lives,” said Humberto Antunes, Partner at Gore Range. “The dermatology arena has tremendous potential and we will be at the forefront of providing value to our partners by driving new and better treatment options for patients.”

“We partnered with Gore Range to access cutting-edge, emerging companies by leveraging their robust deal flow, stringent due diligence, and proven ability to oversee and actively manage their portfolio companies,” said Thorsen Thormann, Vice President, Research at LEO Pharma. “We are committed to nurturing the medical dermatology industry and are excited to have found the right partner to help us invest in innovative new companies.”

Added Gore Range Partner and CEO, Ethan Rigel: “Our experience has been that early and growth-stage companies can really flourish when they have a partner who brings resources and provides guidance and access to relationships that move their businesses from idea to execution. Our work together with LEO Pharma is an example of the approach we are taking that will make a meaningful difference for our portfolio companies. They are an ideal partner for our Strategic Investor Program.”

About Gore Range Capital

Gore Range Capital is a venture capital firm focused on investing in early and growth-stage healthcare businesses. The firm blends the hands-on approach of operationally focused private equity with the early-stage guidance needed in venture capital. Gore Range offers not just capital, but operational, clinical and scientific expertise that leverages deep industry relationships and a renowned scientific advisory board. Based in New York, Gore Range was founded by finance and healthcare professionals with an unrivaled, specialized focus in four core areas: dermatology, cancer, cardiovascular and technology-driven medical innovation. For more information, visit: https://www.gorerangecapital.com/

About LEO Pharma A/S

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,700 people, serving 80 million patients in 130 countries. In 2017, the company generated net sales of euro 1.4 billion. Please visit http://www.leo-pharma.com/

Contacts

Media: Kate Traynor Sloane & Company ktraynor@sloanepr.com 212-486-9500

© Gore Range Capital LLC